Alzheon proposes new IPO seeking $41.2M

Alzheon Inc. (Framingham, Mass.) proposed on Aug. 27 to raise up to $41.2 million in an IPO on NASDAQ underwritten by ThinkEquity.

This year, Alzheon plans to start a Phase Ib trial to evaluate the pharmacokinetics of ALZ-801 in to treat Alzheimer's disease in patients with at least one copy of the apolipoprotein E (APOE) epsilon 4 (APOE4) gene. The company plans to start a Phase IIb trial next half of candidate to treat APOE4-homozygous patients with early to mild AD...